ZGGS18 for Advanced Solid Tumors

Study of ZGGS18 in Patients With Advanced Solid Tumors

Recruiting Phase 1 Phase 2 Interventional Study
Advanced Solid Tumor
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
222 (estimated)
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
Who this trial is looking for

This trial is looking for patients with advanced solid tumors who have not responded to standard treatments. Participants will receive a treatment called ZGGS18 to evaluate how well it works and its safety.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have advanced solid tumors confirmed by medical tests.
  • I have not responded to standard treatments or cannot tolerate them.
  • I have a performance status of 0 or 1.
  • I expect to live for at least 3 more months.
  • I have at least 1 measurable tumor lesion.
  • My measurable lesions are not from radiation therapy or have progressed after such therapy.

You may not be able to join if

  • My doctor feels I am not suitable for this trial.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of advanced solid tumors, who had failed the available standard treatments or no standard treatment or intolerance to standard treatment; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; * Life expect…
Contacts

Shangdi Ning

+86-0512-57018308

ningsd@zelgen.com

CONTACT